ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

PRECISE-ILLUMINA Partnership Agreement

By: 3BL Media

Singapore launches Southeast Asia’s most comprehensive consented population study with 100,000 whole genomes for health and clinical breakthroughs

SOURCE: Illumina

SUMMARY:

Unique large-scale population study will yield insights into Asian-specific diseases, improving population health, patient outcomes, and innovations in the local biomedical technology industry.

DESCRIPTION:

SINGAPORE, May 26, 2022/3BL Media/ – Precision Health Research, Singapore (PRECISE), the central entity implementing Singapore’s National Precision Medicine (NPM) strategy, and Illumina, Inc (Illumina), a leader in genomics technology, announced today a strategic partnership to sequence and analyze 100,000 Singaporean whole genomes (SG100K), to create for the first time, Southeast Asia’s most comprehensive consented population study.

2. Precision Medicine has been identified by Singapore’s Ministry of Health as one of the potential innovative approaches to transform healthcare and address healthcare challenges, and also by the National Research Foundation, Singapore (NRF) as a strategic goal of the Research, Innovation and Enterprise (RIE) 2025 plan to transform and protect the health of Singaporeans. PRECISE, funded by NRF, collaborates with Singapore research and clinical partners to implement and coordinate this effort nationally.

3. The SG100K project, supported under Open Fund – Large Collaborative Grant1, will involve 100,000 consented Singaporean participants, comprising Chinese, Malay and Indian, representative of 80% of the populations across Asia. 

Continue reading the complete article here

Learn more about Illumina here

Tweet me: Sequencing 100,000 Singaporean whole #genomes in a breakthrough study announced today in key partnership with Precision Health Research, Singapore (PRECISE) & @illumina. Learn more here: https://bit.ly/3GvnN4U

KEYWORDS: NASDAQ: ILMN, Precision Health Research, PRECISE, SG100K project, genomics

Photo: Deputy Prime Minister and Coordinating Minister for Economic Policies Heng Swee Keat as Guest-of-Honour, gracing the PRECISE-ILLUMINA Partnership Agreement Ceremony, on 26 May at Illumina’s Woodlands Laboratory.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.